Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446594 | 1.00 | POLB (0.34) | POLB | |
| SCHEMBL15895095 | 0.81 | POLB (0.35) | POLB | |
| SCHEMBL5485586 | 0.79 | — | — | |
| SCHEMBL6131615 | 0.79 | POLB (0.32) | POLB | |
| SCHEMBL10156702 | 0.78 | POLB (0.33) | POLB | |
| Hydrochloric Acid SCHEMBL6131561 | 0.77 | POLB (0.31) | POLB | |
| SCHEMBL15494039 | 0.76 | POLB (0.33) | POLB | |
| SCHEMBL10005608 | 0.75 | POLB (0.39) | POLB | |
| SCHEMBL7128026 | 0.72 | POLB (0.35) | POLB | |
| SCHEMBL5313285 | 0.72 | POLB (0.30) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9629934-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | DYAX CORP. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9446155-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | BRACCO SUISSE SA (CH) | 2016-09-20 | — | — | US | disclosed |
| US-9408926-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | BRACCO SUISSE S.A. (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20140286864-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | BRACCO SUISSE SA (CH) | 2014-09-25 | — | — | US | disclosed |
| EP-2301587-B1 | KDR and VEGF/KDR binding peptides and their use in diagnosis | DYAX CORP (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20140161732-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | BRACCO SUISSE S.A. (CH) | 2014-06-12 | — | — | US | disclosed |
| US-20140107041-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8642010-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | DYAX CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8623822-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | BRACCO SUISSE SA (CH) | 2014-01-07 | — | — | US | disclosed |
| EP-2014310-B1 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | DYAX CORP (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110097275-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | BRACCO SUISSE SA (CH) | 2011-04-28 | — | — | US | disclosed |
| EP-2301587-A2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | Dyax Corporation (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100003195-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2014310-A2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | Dyax Corporation (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20050250700-A1 | KDR and VEGF/KDR binding peptides | BRACCO INTERNATIONAL B.V. (NL) | 2005-11-10 | — | — | US | disclosed |
| US-20050100963-A1 | Multimeric protein comprising endothelial growth factor (VEGF) and kinase domain region (KDR) for use in detection, prevention and treatment of cell proliferative, virral and infectious disorders | DYAX CORPORATION (US) | 2005-05-12 | — | — | US | disclosed |